3 research outputs found
PL-PatchSurfer2: Improved Local Surface Matching-Based Virtual Screening Method That Is Tolerant to Target and Ligand Structure Variation
Virtual
screening has become an indispensable procedure in drug
discovery. Virtual screening methods can be classified into two categories:
ligand-based and structure-based. While the former have advantages,
including being quick to compute, in general they are relatively weak
at discovering novel active compounds because they use known actives
as references. On the other hand, structure-based methods have higher
potential to find novel compounds because they directly predict the
binding affinity of a ligand in a target binding pocket, albeit with
substantially lower speed than ligand-based methods. Here we report
a novel structure-based virtual screening method, PL-PatchSurfer2.
In PL-PatchSurfer2, protein and ligand surfaces are represented by
a set of overlapping local patches, each of which is represented by
three-dimensional Zernike descriptors (3DZDs). By means of 3DZDs,
the shapes and physicochemical complementarities of local surface
regions of a pocket surface and a ligand molecule can be concisely
and effectively computed. Compared with the previous version of the
program, the performance of PL-PatchSurfer2 is substantially improved
by the addition of two more features, atom-based hydrophobicity and
hydrogen-bond acceptors and donors. Benchmark studies showed that
PL-PatchSurfer2 performed better than or comparable to popular existing
methods. Particularly, PL-PatchSurfer2 significantly outperformed
existing methods when apo-form or template-based protein models were
used for queries. The computational time of PL-PatchSurfer2 is about
20 times shorter than those of conventional structure-based methods.
The PL-PatchSurfer2 program is available at http://www.kiharalab.org/plps2/
Knowledge-Based Strategy to Improve Ligand Pose Prediction Accuracy for Lead Optimization
Accurately predicting how a small
molecule binds to its target
protein is an essential requirement for structure-based drug design
(SBDD) efforts. In structurally enabled medicinal chemistry programs,
binding pose prediction is often applied to ligands after a related
compound’s crystal structure bound to the target protein has
been solved. In this article, we present an automated pose prediction
protocol that makes extensive use of existing X-ray ligand information.
It uses spatial restraints during docking based on maximum common
substructure (MCS) overlap between candidate molecule and existing
X-ray coordinates of the related compound. For a validation data set
of 8784 docking runs, our protocol’s pose prediction accuracy
(80–82%) is almost two times higher than that of one unbiased
docking method software (43%). To demonstrate the utility of this
protocol in a project setting, we show its application in a chronological
manner for a number of internal drug discovery efforts. The accuracy
and applicability of this algorithm (>70% of cases) to medicinal
chemistry
efforts make this the approach of choice for pose prediction in lead
optimization programs
Selectivity Data: Assessment, Predictions, Concordance, and Implications
Could
high-quality in silico predictions in drug discovery eventually
replace part or most of experimental testing? To evaluate the agreement
of selectivity data from different experimental or predictive sources,
we introduce the new metric concordance minimum significant ratio
(cMSR). Empowered by cMSR, we find the overall level of agreement
between predicted and experimental data to be comparable to that found
between experimental results from different sources. However, for
molecules that are either highly selective or potent, the concordance
between different experimental sources is significantly higher than
the concordance between experimental and predicted values. We also
show that computational models built from one data set are less predictive
for other data sources and highlight the importance of bias correction
for assessing selectivity data. Finally, we show that small-molecule
target space relationships derived from different data sources and
predictive models share overall similarity but can significantly differ
in details